CTTI Posts IRB Project Info
The Clinical Trials Transformation Initiative (CTTI) is a public-private partnership to identify practices that will increase the quality and efficiency of clinical trials founded by the FDA and Duke University. Recently, at the 48th Annual DIA Meeting, serveral CTTI projects were presented. These included Cynthia Hahn, Research Compliance Officer, Feinstein Institute for Medical Research, presentation, “Use of Central IRBs for Multicenter Clinical Trials” and addressed solicitation of current perceptions of barriers, development of a strategy to address identified barriers, and assessment reactions to proposed solutions to remove barriers.
The “Site Metrics for Study Start Up” project was delivered by Adam Chasse, MHA, Vice President, RxTrials, who explained the data collection, collaboration, and processes of the project.
CTTI posted slideshows and a video on the IRB project.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
